Taiho Ventures backs Storm Therapeutics
UK-based Storm Therapeutics, which focuses on developing small molecule drugs that target RNA-modifying enzymes, has raised 4 million pounds in funding. The investor was Taiho Ventures LLC. In conjunction with the funding, Sakae Asanuma, president of Taiho Ventures, joins Storm Therapeutics' board of directors.
8 January 2018•1 min read
